Literature DB >> 7795258

Human interleukin-3 receptor modulates bcl-2 mRNA and protein levels through protein kinase C in TF-1 cells.

M S Rinaudo1, K Su, L A Falk, S Halder, R A Mufson.   

Abstract

Upon withdrawal of interleukin-3 (IL-3) from human factor-dependent erythroleukemic cell line TF-1, bcl-2 mRNA and protein levels decrease within 8 to 24 hours. Accompanying this decrease is the onset of apoptosis as determined by flow cytometric analysis of DNA degradation. By 8 to 18 hours of deprivation approximately 70% to 80% of the cells have entered apoptosis. Downregulation of protein kinase (PK) by a 24-hour incubation in 100 nmol/L 12-O-tetradecanoyl-phorbol-13-acetate (TPA) in the presence of IL-3 dramatically reduced bcl-2 mRNA levels, and induced apoptosis in the presence of IL-3. We have also found that even in the presence of IL-3, two inhibitors of PKC, light-activated calphostin and H-7, substantially reduced the levels of bcl-2 mRNA between 8 and 24 hours as measured by a semi-quantitative reverse transcriptase/polymerase chain reaction assay method; however, the cyclic nucleotide-dependent PK inhibitor HA 1004, that is a structural analog of H-7 but a poor inhibitor of PKC, did not reduce bcl-2 levels in the presence of IL-3. This decrease in bcl-2 mRNA was accompanied by a decline in bcl-2 protein levels by 8 to 24 hours after addition of light-activated calphostin. In addition to interfering with the maintenance of bcl-2 mRNA levels, inhibition of PKC with H-7 inhibited the induction of bcl-2 mRNA in factor-deprived TF-1 cells restimulated with IL-3. The cyclic nucleotide-dependent PK inhibitor HA 1004 did not inhibit IL-3-induced bcl-2 mRNA. Studies with actinomycin D showed that transcription plays a major role in maintaining bcl-2 levels in TF-1 cells, and it is therefore likely that IL-3 plays a role in maintaining bcl-2 transcription through activation of PKC in these cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7795258

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway.

Authors:  T Skorski; A Bellacosa; M Nieborowska-Skorska; M Majewski; R Martinez; J K Choi; R Trotta; P Wlodarski; D Perrotti; T O Chan; M A Wasik; P N Tsichlis; B Calabretta
Journal:  EMBO J       Date:  1997-10-15       Impact factor: 11.598

Review 2.  Crossing paths: interactions between the cell death machinery and growth factor survival signals.

Authors:  Gabriela Brumatti; Marika Salmanidis; Paul G Ekert
Journal:  Cell Mol Life Sci       Date:  2010-02-16       Impact factor: 9.261

3.  IL-33/ST2 axis promotes mast cell survival via BCLXL.

Authors:  Jun-Xia Wang; Shinjiro Kaieda; Sarah Ameri; Nadia Fishgal; Daniel Dwyer; Anthony Dellinger; Christopher L Kepley; Michael F Gurish; Peter A Nigrovic
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-30       Impact factor: 11.205

4.  Evaluation of the BCL-2 gene locus as a susceptibility locus linked to the clinical expression of systemic lupus erythematosus (SLE).

Authors:  Q R Huang; D Morris; N Manolios
Journal:  Rheumatol Int       Date:  1996       Impact factor: 2.631

5.  Trophic factor withdrawal: p38 mitogen-activated protein kinase activates NHE1, which induces intracellular alkalinization.

Authors:  A R Khaled; A N Moor; A Li; K Kim; D K Ferris; K Muegge; R J Fisher; L Fliegel; S K Durum
Journal:  Mol Cell Biol       Date:  2001-11       Impact factor: 4.272

6.  Induction of bcl-2 expression by phosphorylated CREB proteins during B-cell activation and rescue from apoptosis.

Authors:  B E Wilson; E Mochon; L M Boxer
Journal:  Mol Cell Biol       Date:  1996-10       Impact factor: 4.272

Review 7.  Progress towards mechanism-based treatment for Diamond-Blackfan anemia.

Authors:  Sara E Sjögren; Johan Flygare
Journal:  ScientificWorldJournal       Date:  2012-04-24

8.  Interleukin 3 prevents delayed neuronal death in the hippocampal CA1 field.

Authors:  T C Wen; J Tanaka; H Peng; J Desaki; S Matsuda; N Maeda; H Fujita; K Sato; M Sakanaka
Journal:  J Exp Med       Date:  1998-08-17       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.